This ranking is built on documented specifications and regulatory standing, not on tasting. No product here carries a score, because scores on this site come only from products actually used. What it does tell you is which pouches are authorised, at what strength, by whom, and what the evidence and the regulators actually say.
How to read this page. Every “best of” list in this category is somebody’s palate presented as a verdict. That has a place — but it is not what this page is, and pretending otherwise would be dishonest. Scored reviews are published product by product as each one is used, and this ranking will be rebuilt around them as they arrive. Until then, everything below is traceable to an FDA order, a corporate filing or a peer-reviewed paper.
What “best” can honestly mean before anyone has tasted anything
Strip out flavour and four questions remain, and they are the ones that actually determine whether a product is a sensible choice.
Is it lawfully sold where you are? In the United States this has a documentary answer. The FDA publishes the list of authorised nicotine pouch products, and states that these “are the only nicotine pouch products that may be lawfully sold in the United States.” In Europe the answer varies by country, and in several countries it is no.
Is the strength stated, and by whom? For FDA-authorised products the milligram figure is in the order itself. For most of the rest of the category it is not published by the manufacturer at all.
Has anyone assessed it against a standard? A marketing authorisation means a regulator reviewed a dossier and concluded the product offers greater benefit to population health than risk. It does not mean the product is safe. It is still the strongest external check that exists.
Does the maker disclose anything? Volumes, ownership, manufacturing location, strength ladders. Companies that publish are easier to hold to account than companies that do not.
Those four are the ranking. They are not a substitute for knowing whether you will like something. They are the part that can be checked.
The ranking
1. ZYN, 3 mg and 6 mg — the most thoroughly documented pouch on sale
Ten flavours at two strengths: Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint, Wintergreen. Authorised by the FDA on 16 January 2025, the first nicotine pouches ever authorised.
What puts it first is not popularity. It is that these twenty products are the only pouches in the world holding a second FDA order: a modified risk tobacco product authorisation, granted 30 June 2026 for five years, permitting one specific claim — “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”
Read that claim exactly as written. It is comparative, it is against cigarettes, and the FDA published it alongside the sentence “There is no safe tobacco product, and those who do not use tobacco products should not start.” The agency also said that for adults who smoke, “fully quitting the use of all forms of tobacco products would most benefit their health”.
The 3 mg and 6 mg dry cans move to 20 pouches per can in the fourth quarter of 2026.
2. on! PLUS, 6 mg and 9 mg — the documented mid-to-strong option
Mint, Tobacco and Wintergreen, each at 6 mg and 9 mg, from Helix Innovations. These were the first decisions under the FDA’s accelerated review pilot, announced 13 January 2026.
Second rather than first because there is no modified risk order here — only a marketing authorisation. That is not a criticism of the product; it is a smaller pile of paper.
3. ZYN ULTRA, 9 mg and 11 mg — the strongest authorised pouches
Eleven products authorised 21 August 2026: ten flavours at 9 mg plus a single 11 mg variant. A moist format rather than the dry standard ZYN, at 20 pouches per can.
Third, not because it is weaker in effect but because it is newer, has no modified risk order, and is a different format from the line that earned ZYN its documentation. One specific warning, since this is where the marketing gets sloppy: the ZYN modified risk claim does not apply to ULTRA. If you see the lower-risk wording on an ULTRA can or an ULTRA shelf-talker, it has been stretched beyond what the FDA authorised.
The FDA’s own basis for the decision was comparative: the products “contain lower levels of most harmful and potentially harmful constituents (HPHCs) when compared to other oral and smokeless tobacco products.”
4. on!, 2 mg and 4 mg — the lowest authorised strengths
Autumn Spice, Cappuccino and Rich Berry, at 2 mg and 4 mg. Four of these were authorised on 4 August 2026 under the pilot programme.
Ranked fourth on documentation, but first on one practical axis: these are the lowest nicotine strengths available with an FDA authorisation behind them. For anyone who finds 6 mg more than they want, the authorised alternatives are here and nowhere else.
Tier two: sold widely, no FDA authorisation
VELO, Rogue, FRE, Zone, Black Buffalo, White Fox, Siberia, Oden’s, Skruf, Klint, Loop and others are not on the FDA’s authorised list. Not one of them.
This is not a statement about quality, and several of these are large, long-established products with serious manufacturing behind them. It is a statement about paperwork, and it produces the strangest fact in the category: BAT reported 3.2 billion US Modern Oral pouches in the first half of 2026 and a 29.8% US volume share, up 11.6 percentage points, for a portfolio with no authorised products.
I cannot rank tier two against tier one on documentation, because for most of tier two the documentation does not exist — no published strengths, no regulatory assessment, in several cases no verifiable ownership. What I can do is tell you that, and point at the brand directory, where each entry is marked verified, partially verified or unverified.
The authorised list in full
| Brand | Strengths | Flavours | Authorised | Modified risk order |
|---|---|---|---|---|
| ZYN | 3 mg, 6 mg | Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint, Wintergreen | 16 Jan 2025 | Yes — 30 Jun 2026, five years |
| ZYN ULTRA | 9 mg, 11 mg | Chill, Citrus, Cool Mint, Deep Freeze, Menthol, Peppermint, Smooth, Spearmint, Wintergreen, Wintergreen Chill | 21 Aug 2026 | No |
| on! PLUS | 6 mg, 9 mg | Mint, Tobacco, Wintergreen | Announced 13 Jan 2026 | No |
| on! | 2 mg, 4 mg | Autumn Spice, Cappuccino, Rich Berry | 4 Aug 2026 (and a further order 19 Aug 2026) | No |
Forty-three products in total, from two companies: Swedish Match USA with 31 and Helix Innovations with 12. The list was last updated on 21 August 2026, and it has grown in every one of the last three years, so check it rather than this table if you are buying on the strength of it.
Choosing by strength, not by rank
The most useful thing this page can do is stop you buying the wrong strength, which is the single most common mistake in the category.
| If you want | Authorised options | Note |
|---|---|---|
| The lowest available | on! 2 mg | The lowest strength with an FDA order behind it |
| Low | ZYN 3 mg, on! 4 mg | ZYN’s dry ladder also runs to 1.5 mg following the September 2026 expansion |
| Mid | ZYN 6 mg, on! PLUS 6 mg | The most widely stocked tier in the US |
| Strong | on! PLUS 9 mg, ZYN ULTRA 9 mg | Different formats — one dry, one moist |
| Strongest authorised | ZYN ULTRA 11 mg | A single SKU |
Two warnings about the numbers themselves.
First, milligrams per pouch is a statement of content, not of delivery. How much nicotine actually reaches you depends on the pouch base, moisture, pH and how you use it. A 6 mg pouch from one maker and a 6 mg pouch from another are not interchangeable, and our strengths guide goes through why.
Second — and this is new evidence, published this month — how people actually use pouches varies far more than the research protocols assume. A qualitative study in Nicotine & Tobacco Research on 15 September 2026 found wide variation in placement, duration and handling among established users, concluding that “ONP use patterns vary among established users” and that future work on abuse liability and toxicity “should consider effects across different use topographies.” In plain terms: the same can behaves differently in different mouths, and the laboratory numbers are narrower than they look.
What the evidence actually supports
A ranking page is where overclaiming happens, so here is the evidence position stated flatly, with the sources attached.
The most recent synthesis is an updated scoping review published in Nicotine & Tobacco Research on 6 September 2026 by Travis, Warner, Hartmann-Boyce, Goniewicz, Ma, Meza and Levy. Its summary line is the most accurate single sentence available on this subject: “ONPs are considerably less toxic than cigarettes, but their long-term health impacts remain understudied.” Its conclusion “underscores the need for further research on ONP health effects, their efficacy in long-term smoking cessation, and broader public health impact in tobacco-naïve populations.”
Three things follow, and none of them is a marketing line.
No product on this page is safe. The FDA says so on its own authorised-products list: authorisation “does not mean these products are safe, nor are they ‘FDA approved.'”
No product on this page is a way of quitting. Nicotine pouches are not licensed cessation treatments, and the evidence on whether they help people stop smoking long-term is, in the reviewers’ own word, understudied. If stopping is the goal, licensed treatment and behavioural support have an evidence base these products do not.
The comparative claim is the only authorised health claim in the category, it belongs to twenty ZYN products, it expires in 2031 unless renewed, and it is about switching from cigarettes.
Outside the United States
This ranking is built on a US regulatory framework, and it does not transfer. Nicotine pouches are banned outright in France, Belgium and the Netherlands — this page is not buying advice for those markets, and no amount of product ranking changes the legal position there. Denmark and Finland restrict flavours and cap nicotine content. Canada restricts sale to pharmacies with a prescription threshold. The United Kingdom passed the Tobacco and Vapes Act in April 2026, with much of the detail, including an expected nicotine cap, still to arrive in secondary legislation.
If you are outside the US, read the regulation tracker first and this page second. Which product is documented matters much less than whether it is legal where you live.
What is missing from this ranking, and when it arrives
Everything that makes a pouch pleasant to use is absent from this page. Flavour accuracy and how long it lasts. Whether the nicotine arrives smoothly or in a rush. How the fleece sits under the lip after twenty minutes. Whether the can is any good. Batch-to-batch consistency. Those are the six things this site scores, and they are scored from cans that have been used.
As scored reviews publish, they replace the entries above and the ranking reorders around them. The ZYN Wintergreen 6 mg first look is an example of the interim state: fully documented, explicitly unscored.
If you want a ranking based on somebody’s palate today, plenty of sites will give you one. I would rather publish a shorter, duller page that is true.
What an FDA authorisation actually is
The word “authorised” is doing a lot of work on this page, so it is worth setting out what the three different FDA decisions in the table above actually are. They are not the same thing, and the differences explain the ranking order.
A marketing granted order (PMTA). The manufacturer submits a premarket tobacco product application, and the agency decides whether permitting the product is appropriate for the protection of public health. The test the FDA describes is whether there is “sufficient evidence that the new products offer greater benefits to population health than risks” — a population-level judgement that weighs adults switching from more harmful products against the risk of uptake by people who would not otherwise use nicotine. It is not a safety finding about an individual can.
A modified risk tobacco product order (MRTP). A separate, higher bar, and the only route by which any comparative health claim may lawfully appear on a pouch in the United States. Twenty ZYN products hold one; nothing else in the category does. It runs five years and the FDA has said it may be withdrawn if there is a significant increase in youth uptake or if continued marketing stops benefiting population health.
The accelerated review pilot. A process change rather than a different standard. The FDA launched it to shorten review timelines and has framed the results as showing that “rigorous and efficient standards of scientific review are not mutually exclusive.” The on! PLUS decisions came through it, and by the agency’s count 23 of the 43 authorised pouch products have now been decided this way.
The practical reading for a buyer: a PMTA order tells you a regulator looked at the dossier. An MRTP order tells you a regulator also accepted a specific, narrow comparative claim. Neither tells you the product is safe, and the FDA says so itself on the page that lists them.
Dry and moist are different products, not different flavours
The authorised list contains both formats and the distinction gets lost at shelf level.
Dry pouches — standard ZYN, and on! — contain less moisture. They tend to start slower and are generally regarded as less messy, which is why they dominate the American market that grew up around them.
Moist pouches — ZYN ULTRA, and the Scandinavian white pouch tradition generally — carry more liquid. More moisture usually means faster onset, at the cost of more drip.
The reason to care is that the milligram figure does not carry across the two. A 9 mg moist pouch and a 9 mg dry pouch have the same nicotine content and can behave quite differently, and the new topography research makes the same point from the user’s side: how a person holds and handles a pouch changes the outcome, and the variation between people is wide. If you are switching format, treat the strength number as a rough guide and expect to recalibrate.
The six things a scored review will measure
So you know what this page is waiting on, here is what a scored review on this site actually assesses. Each is scored from cans that have been used, over more than one session:
- Flavour accuracy — does it taste like the thing on the label, and is the flavour clean or synthetic?
- Flavour duration — how long before it fades, and does it fade before the nicotine does?
- Nicotine delivery — onset, peak, and whether the arrival is smooth or abrupt.
- Comfort — fit under the lip, seam quality, burn or irritation over a full session.
- Moisture behaviour — drip, and how the pouch changes across twenty or thirty minutes.
- Consistency and packaging — batch-to-batch variation, and whether the can does its job.
None of those can be read off a filing, which is the whole reason this page carries no scores today. It is also why the ranking above is stated as what it is — a documentation ranking — rather than dressed up as a verdict.
What to check before you buy
- The strength, against the ladder above. Going too strong is the most common first mistake, and the least pleasant.
- The format. Dry or moist, and whether you are switching between them.
- The can count. ZYN’s 3 mg and 6 mg dry cans move to 20 pouches in the fourth quarter of 2026; comparing prices across a 15-count and a 20-count can without noticing is an easy way to misjudge value.
- Whether it is on the FDA list, if you are in the United States and that matters to you. The list is short and searchable.
- Whether it is legal where you are, if you are not. In several European countries the answer is no, regardless of what an online seller will ship.
Frequently asked
What is the best nicotine pouch? On documentation, ZYN 3 mg and 6 mg: they are the only pouches holding both an FDA marketing authorisation and a modified risk order. On taste, this page does not answer that yet, deliberately.
What is the strongest legal nicotine pouch in the US? ZYN ULTRA at 11 mg is the strongest product on the FDA’s authorised list.
What is the weakest? on! at 2 mg.
Why is VELO not ranked? No VELO product appears on the FDA’s authorised list, and BAT does not publish nicotine strengths for the brand. There is nothing to rank it on.
Are nicotine pouches safer than cigarettes? The published evidence says they are considerably less toxic than cigarettes, and the FDA has authorised one brand to say a narrow version of that. Both sources also say the long-term effects are understudied and that no tobacco product is safe.
Can they help me quit smoking? They are not approved cessation treatments and the evidence on long-term quitting is thin. Ask a clinician about treatments that do have one.
How often does this page change? Whenever the FDA list changes or a scored review publishes.
Sources
- FDA — Nicotine Pouch Products Authorized by the FDA (current as of 21 August 2026)
- FDA — 20 ZYN products authorised, 16 January 2025
- FDA — ZYN modified risk order, 30 June 2026
- FDA — 11 ZYN ULTRA products, 21 August 2026
- FDA — 6 on! PLUS products, 13 January 2026
- FDA — 4 on! products, 4 August 2026
- Travis et al., updated scoping review, Nicotine & Tobacco Research, 6 September 2026
- Tomko et al., oral nicotine pouch use topography, Nicotine & Tobacco Research, 15 September 2026
- BAT — half-year 2026 announcement
- PMI US — ZYN portfolio expansion, 9 September 2026
Last verified: 21 September 2026. No affiliate links, no sponsored placements, no paid entries — and if that ever changes it will be declared at the top of the page, not the bottom.
Nicotine is addictive. No tobacco or nicotine product is safe, and completely stopping is the lowest-risk option. This site is for adults who already use nicotine — 21+ in the United States, 18+ or your local legal age elsewhere. Nothing here is medical advice.